Skip to content
OpenCapital
Get started

Viatris VTRS Norvasc — Net Sales

Other product segments

Brands
$2.33B+10.2%
Generics
$1.18B+4.5%
Lipitor
$462M+19.1%
Lyrica ®
$120.6M+7.1%
EpiPen® Auto-Injectors
$101.1M+4.6%
Creon ®
$97.4M+18.2%
Viagra ®
$95M-3.6%
Zoloft ®
$72.6M+20.6%
Celebrex ®
$67.1M+5.8%
Yupelri ®
$62.5M+7.2%
Effexor ®
$62M+4.6%
Xalabrands
$39.2M+5.7%
Dymista ®
$37.3M-12.9%
Xanax ®
$34.8M+7.7%

Similar metrics at other companies

Medtronic logo
MDTCardiovascular — Net Sales
$3.8B+13.8%
Nature's Sunshine Products logo
NATRCardiovascular — Net Sales
$20.34M-0.8%
Boston Scientific logo
BSXCardiovascular — Net Sales
$3.5B+13.5%
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
Stryker logo
SYKVascular — Net Sales
$517M+27.3%
Medline, Inc. logo
MDLNMedline Brand — Net Sales
$3.47B+6.2%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.49B+81.7%
Enterprise value$31.3B+29.5%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's norvasc — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's norvasc — net sales?
Viatris (VTRS) reported norvasc — net sales of $210M in Q1 2026.
How has Viatris's norvasc — net sales changed year-over-year?
Viatris's norvasc — net sales increased by 21.9% year-over-year, from $172.3M to $210M.
What is the long-term trend for Viatris's norvasc — net sales?
Over 4 years (2021 to 2025), Viatris's norvasc — net sales has grown at a -3.7% compound annual growth rate (CAGR), from $824.7M to $709.9M.
What does norvasc — net sales mean?
This metric represents the total revenue generated from the global sales of Norvasc, a branded calcium channel blocker used to treat hypertension and angina. As a legacy pharmaceutical product, it serves as a key component of the company's established brands portfolio, contributing to stable cash flows. Tracking these sales provides insight into the performance of mature, off-patent assets within the company's broader pharmaceutical product mix.